Robin Bannister

Subpage image
Loading
Robin Bannister

Robin Bannister

CEO Strategy and Business Development, SEEKACURE Ltd
Robin is the discoverer and scientist behind Flarin. Robin Bannister joined the Group in 2008 when his Company, Biocopea was acquired by SEEK – then known as PepTcell. Robin focuses on the discovery of novel biology based upon existing drugs and drug templates and the subsequent identification and exploitation of high–value, low-risk products. Robin is a successful drug-discovery and development entrepreneur. Before founding Biocopea, Robin co-founded Arakis, which successfully discovered, developed and licensed a pipeline of products and was acquired by Sosei Corporation in 2005. Arakis’ pipeline was the basis for successfully raising over £50m during a five-year period. Arakis licensed its lead product to Novartis, in the largest European biotech deal in 2005, with a headline value of $325m and was subsequently sold to Sosei Corporation in the same year. Robin served on the Board of Sosei until leaving in 2008. Prior to this, Robin was at Chiros, Chiroscience and Celltech (as Preclinical Development Director). Robin’s early career was at Smith Kline and French. Robin is a chemist by background training and studied at Imperial College, London receiving his PhD in 1988.
Sessions

In association with

Pfizer

Supported by

Education Partners

Sponsored by

Charity Partner

Official Media Partner


CIG

Official Publications

Digital Media Partner


C+D

Natural Education Partner

Natural Pharmacy Business

Media partners